All Episodes
|
153
|
David Stewart

#153: Overcoming the Costly Roadblocks to Developing Novel Cancer Therapies, with Dr. David Stewart

Oct 21, 2021

Episode Summary

Dr. David Stewart is a renowned oncologist and the author of A Short Primer on Why Cancer Still Sucks. United with the desire to heal patients suffering from advanced lung cancer is his drive to resolve the numerous and expensive barriers to novel cancer therapy development and utilization. In today’s episode, Dr. Stewart reviews the root causes of some of these blockades and discusses just how costly they will continue to be if we can’t overcome them.

Episode Notes

David Stewart, MD; Head, Division of Medical Oncology, University of Ottawa; Author, A Short Primer on Why Cancer Still Sucks

Dr. Stewart received his MD degree from Queen’s University, Kingston, followed by training in internal medicine at McGill University and in medical oncology in the Department of Developmental Therapeutics at the UT MD Anderson Cancer Center. He first moved from MD Anderson to the University of Ottawa in 1980, and served as Chief of Medical Oncology at the Ottawa Civic Hospital from 1989 to 1999. He returned to the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center from 2003 to 2011 where he served as Chief of the Section of Experimental Therapeutics (2003-2005), Chair Ad Interim (2005), Deputy Chair (2006-2009), and Director of Translational Research (2009-2011). He was also the Principle Investigator of MD Anderson’ phase II N01 contract with the National Cancer Institute, and was the clinical leader of a number of other federally-funded translational research projects. In 2011, Dr. Stewart returned to Ottawa from the University of Texas MD Anderson Cancer Center (Houston, TX) in 2011 to assume the position of Head of the Division of Medical Oncology at The Ottawa Hospital and the University of Ottawa.

John Marchica, CEO, Darwin Research Group

John Marchica is a veteran health care strategist and CEO of Darwin Research Group. He is leading ongoing, in-depth research initiatives on integrated health systems, accountable care organizations, and value-based care models. He is a faculty associate in the W.P. Carey School of Business and the graduate College of Health Solutions at Arizona State University.

John did his undergraduate work in economics at Knox College, has an MBA and M.A. in public policy from the University of Chicago, and completed his Ph.D. coursework at The Dartmouth Institute. He is an active member of the American College of Healthcare Executives and is pursuing certification as a Fellow.

About Darwin Research Group

Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

CONNECT WITH US:

🌐 Visit us on the web

🌐 Follow Health Care Rounds on LinkedIn

🌐 Follow Darwin Research Group on LinkedIn

📺 Watch Health Care Rounds on YouTube

🎧 Listen on Apple Podcasts

🎧 Listen on Spotify

⚙️ Health Care Rounds is produced by Grippi Media

Recommended Next

Podcast 197: Making Health Care Costs Simple and Transparent w/ Mark Cuban, Co-Founder, Cost Plus Drugs
Podcast 196: Physician Leadership in a New Era of Health Care w/ Dr. Sowmya Viswanathan, Baycare
Podcast 195: Why Primary Care Is Under Strain w/ Dr. Greg Whisman, Chief Medical Officer, CareMore Health
Podcast 194: Why Health Care Reform Keeps Failing w/ Dr. David Shulkin
Podcast 193: The New Model for Specialty Pharmacy w/ Jigar Thakkar, PharmD
Podcast 192: Making Value-Based Care Work at Scale w/ David Carmouche, MD
Podcast 191: Curing Nursing Burnout Through Education w/ Dr. Adele Webb
Podcast 190: The New Rules of Health System Leadership w/ John D’Angelo, MD, FACEP

Recommended Content

Browse Library
INsights
January 14, 2026

Darwin's Our Take: Lilly’s ‘triple G’ candidate exceeds analysts’ expectations

Read More
INsights
January 5, 2026

Darwin's Our Take: FDA approves Novo Nordisk’s Wegovy pill

Read More
INsights
December 22, 2025

Darwin's Our Take: Another 9 drugmakers agree to most-favored-nation pricing on certain products

Read More
Stay Aware. Stay Informed.

Subscribe to Our Take

Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.